A phase 2 study investigating osimertinib as second-line treatment in patients with EGFR-mutated non-small cell lung cancer who have progressed on prior EGFR tyrosine kinase inhibitor therapy. The study aims to evaluate response rate and duration of response.
For full eligibility, visit ClinicalTrials.gov.
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →